William Bartek, MD
Critical Care Medicine · Austin, TXNPI 1598722522
Payments from drug & device makers
Across 457 payments — averaging $622.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$281K
- Johnson & Johnson$1K
- Boehringer Ingelheim$480
- GSK$291
- AstraZeneca$189
- United Therapeutics Corporation$149
- plus $762 from 20 others
What the payments were for
- Speaking & faculty fees$13,2005%
- Travel & lodging$37,91013%
- Food & beverage$13,4945%
- Education$219,28777%
- Gifts$4670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 360 | $281,456 |
| Johnson & Johnson | 11 | $1,033 |
| Boehringer Ingelheim | 16 | $480 |
| GSK | 17 | $291 |
| AstraZeneca | 9 | $189 |
| United Therapeutics Corporation | 6 | $149 |
| Insmed, Inc. | 7 | $124 |
| Verona Pharma, Inc. | 3 | $72 |
| Electromed, Inc. | 5 | $72 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Advanced Respiratory, Inc | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Sanofi | 1 | $31 |
| Mylan Specialty L.p. | 1 | $28 |
| Inogen, Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $19 |
| 3b Medical, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$271,534
- DA VINCI SP$7,000
- Monarch Platform$725
- OFEV$104
How this compares
$284,358 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $285,092 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 235 | $236,795 |
| Breo ElliptaFluticasone/Vilanterol | 119 | $65,333 |
| Spiriva RespimatTiotropium Bromide | 70 | $54,882 |
| Dupixent PenDupilumab | 14 | $52,180 |
| NucalaMepolizumab | 11 | $38,467 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $34,549 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $24,714 |
| Spiriva HandihalerTiotropium Bromide | 42 | $21,409 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $14,426 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $10,986 |
| Pirfenidone | 12 | $9,179 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $7,813 |
| Arnuity ElliptaFluticasone Furoate | 24 | $7,650 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 210 | $7,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $480 | $388,949150 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $291 | $379,808466 claims |
| AstraZenecaSymbicort, Airsupra | $189 | $12,68526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Austin
- Sean GilbeyAustin$723K
- Matthew AndersonAustin$314K
- Subramaniyam RajanAustin$98K
- John HinzeAustin$28K
- Cynthia ZamoraSan Antonio$6.4M
- Rishi RajLubbock$1.9M
- Carlo HatemEl Paso$1.6M
- Deepa GoturHouston$1.1M
- Matt KhoshnevisHouston$759K
- Rodeo AbrencilloHouston$616K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.